

**Fig. 3.** Cell growth rate analysis of hMSCs contaminated with HeLa cells. (A) The Y-axis indicates the growth rate (doubling per day) of hMSCs. The results of three lots of hMSCs are presented (Lot 1, 2, and 3). (B) The growth rates of three lots of hMSCs are plotted along the passage numbers. Data are represented as mean  $\pm$  S.E.M. of the three lots. Statistical significance was determined using two-way repeated measures ANOVA and Student–Newman–Keuls's post-hoc test (\* $P < 0.05$  compared with the rate at  $P = 5$ ).

### Author contributions

Conceived and designed the experiments: KK NT SY RS YS. Performed the experiments: KK NT. Analyzed and Interpreted the data: KK NT SY RS SN AM YS. Contributed reagents/materials/analysis tools: SN AM YS. Wrote the paper: KK NT SY YS. Acquired the funding: AM YS.

### Competing interests


The authors have declared that no competing interests exist.

### Acknowledgments

This work was supported by Research Grants from the Japanese Ministry of Health, Labour and Welfare (H23-SAISEI-IPPAN-005, H24-IYAKU-SHITEI-027, H25-JITSUYOKA(SAISEI)-IPPAN-008, and Marketing Authorization Facilitation Program for Innovative Therapeutic Products).

### References

- [1] Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* 2007;131:861–72.
- [2] Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, et al. Embryonic stem cell lines derived from human blastocysts. *Science* 1998;282:1145–7.
- [3] Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, et al. Induced pluripotent stem cell lines derived from human somatic cells. *Science* 2007;318:1917–20.
- [4] Kuroda T, Yasuda S, Sato Y. Tumorigenicity studies for human pluripotent stem cell-derived products. *Biol Pharm Bull* 2013;36:189–92.
- [5] Prockop DJ. Defining the probability that a cell therapy will produce a malignancy. *Mol Ther* 2010;18:1249–50.
- [6] Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. *Nat Med* 2004;10:789–99.
- [7] Blagosklonny MV. Target for cancer therapy: proliferating cells or stem cells. *Leukemia* 2006;20:385–91.
- [8] Rubio D, Garcia-Castro J, Martin MC, de la Fuente R, Cigudosa JC, Lloyd AC, et al. Spontaneous human adult stem cell transformation. *Cancer Res* 2005;65:3035–9.
- [9] Rosland GV, Svendsen A, Torsvik A, Sobala E, McCormack E, Immervoll H, et al. Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. *Cancer Res* 2009;69:5331–9.
- [10] Wang Y, Huso DL, Harrington J, Kellner J, Jeong DK, Turney J, et al. Outgrowth of a transformed cell population derived from normal human BM mesenchymal stem cell culture. *Cytherapy* 2005;7:509–19.
- [11] Tang DQ, Wang Q, Burkhardt BR, Litherland SA, Atkinson MA, Yang LJ. In vitro generation of functional insulin-producing cells from human bone marrow-derived stem cells, but long-term culture running risk of malignant transformation. *Am J Stem Cells* 2012;1:114–27.
- [12] Torsvik A, Rosland GV, Svendsen A, Molven A, Immervoll H, McCormack E, et al. Spontaneous malignant transformation of human mesenchymal stem cells reflects cross-contamination: putting the research field on track – letter. *Cancer Res* 2010;70:6393–6.
- [13] de la Fuente R, Bernad A, Garcia-Castro J, Martin MC, Cigudosa JC. Retraction: spontaneous human adult stem cell transformation. *Cancer Res* 2010;70:6682.
- [14] Dirks WG, MacLeod RA, Nakamura Y, Kohara A, Reid Y, Milch H, et al. Cell line cross-contamination initiative: an interactive reference database of STR profiles covering common cancer cell lines. *Int J Cancer* 2010;126:303–4.
- [15] Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. *Exp Cell Res* 1961;25:585–621.
- [16] Hayflick L. The cell biology of aging. *Clin Geriatr Med* 1985;1:15–27.
- [17] Hayflick L. The limited in vitro lifetime of human diploid cell strains. *Exp Cell Res* 1965;37:614–36.
- [18] European medicines Agency EMEA/724428/2009 assessment report for ChondroCelect. 2009.
- [19] Kuroda T, Yasuda S, Kusakawa S, Hirata N, Kanda Y, Suzuki K, et al. Highly sensitive in vitro methods for detection of residual undifferentiated cells in retinal pigment epithelial cells derived from human iPS cells. *PLoS One* 2012;7:e37342.
- [20] Rangarajan A, Hong SJ, Gifford A, Weinberg RA. Species- and cell type-specific requirements for cellular transformation. *Cancer Cell* 2004;6:171–83.



## Original article

# Characterization of *in vivo* tumorigenicity tests using severe immunodeficient NOD/Shi-scid IL2R $\gamma^{\text{null}}$ mice for detection of tumorigenic cellular impurities in human cell-processed therapeutic products



Shinji Kusakawa<sup>a, b</sup>, Kazuhiko Machida<sup>c</sup>, Satoshi Yasuda<sup>a, b</sup>, Nozomi Takada<sup>a, d, 1</sup>, Takuya Kuroda<sup>a, b</sup>, Rumi Sawada<sup>a</sup>, Hanayuki Okura<sup>d, 1</sup>, Hideki Tsutsumi<sup>c</sup>, Shin Kawamata<sup>b</sup>, Yoji Sato<sup>a, b, e, f, g, \*</sup>

<sup>a</sup> Division of Cell-Based Therapeutic Products, National Institute of Health Sciences, Tokyo, Japan

<sup>b</sup> Foundation for Biomedical Research and Innovation, Kobe, Japan

<sup>c</sup> Testing Department, Central Institute for Experimental Animals, Kawasaki, Japan

<sup>d</sup> Platform for Realization of Regenerative Medicine, Foundation for Biomedical Research and Innovation, Kobe, Japan

<sup>e</sup> Department of Quality Assurance Science for Pharmaceuticals, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan

<sup>f</sup> Department of Cellular and Gene Therapy Products, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan

<sup>g</sup> Department of Translational Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan

## ARTICLE INFO

## Article history:

Received 11 September 2014

Received in revised form

14 December 2014

Accepted 28 December 2014

## Keywords:

Tumorigenicity test

NOG mice

Cellular therapy

Regenerative medicine

Quality control

## ABSTRACT

The contamination of human cell-processed therapeutic products (hCTPs) with tumorigenic cells is one of the major concerns in the manufacturing and quality control of hCTPs. However, no quantitative method for detecting the tumorigenic cellular impurities is currently standardized. NOD/Shi-scid IL2R $\gamma^{\text{null}}$  (NOG) mice have shown high xeno-engraftment potential compared with other well-known immunodeficient strains, e.g. nude mice. Hypothesizing that tumorigenicity test using NOG mice could be a sensitive and quantitative method to detect a small amount of tumorigenic cells in hCTPs, we examined tumor formation after subcutaneous transplantation of HeLa cells, as a model of tumorigenic cells, in NOG mice and nude mice. Sixteen weeks after inoculation, the 50% tumor-producing dose (TPD<sub>50</sub>) values of HeLa cells were stable at  $1.3 \times 10^4$  and  $4.0 \times 10^5$  cells in NOG and nude mice, respectively, indicating a 30-fold higher sensitivity of NOG mice compared to that of nude mice. Transplanting HeLa cells embedded with Matrigel in NOG mice further decreased the TPD<sub>50</sub> value to  $7.9 \times 10$  cells, leading to a 5000-fold higher sensitivity, compared with that of nude mice. Additionally, when HeLa cells were mixed with  $10^6$  or  $10^7$  human mesenchymal stem cells as well as Matrigel, the TPD<sub>50</sub> values in NOG mice were comparable to those of HeLa cells alone with Matrigel. These results suggest that the *in vivo* tumorigenicity test using NOG mice with Matrigel is a highly sensitive and quantitative method to detect a trace amount of tumorigenic cellular impurities in human somatic cells, which can be useful in the quality assessment of hCTPs.

© 2015, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. All rights reserved.

\* Corresponding author. 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan. Tel./fax: +81 3 3700 9373.

E-mail address: [yoji@nihs.go.jp](mailto:yoji@nihs.go.jp) (Y. Sato).

Peer review under responsibility of the Japanese Society for Regenerative Medicine.

<sup>1</sup> Present address: Research on Disease Bioresources, Platform of Therapeutics for Rare Disease and Health Policy, National Institute of Biomedical Innovation, Kobe, Japan.

## 1. Introduction

Cell-processed therapeutic products (CTPs) derived from human somatic/stem cells are eagerly expected to treat patients with severe diseases involving functional damage of organs and tissues. To transplant hCTPs into patients, however, tumorigenicity is raised as one of the issues of these products. Tumorigenicity is defined as the capacity of a cell population transplanted into an animal model to



produce a tumor by proliferation at the site of transplantation and/or at a distant site by metastasis [1]. Assessment of tumorigenicity is quite important to manufacture products with consistent quality. Currently, the World Health Organization (WHO) Technical Report Series (TRS) No. 878 Annex 1 is the only international guideline that addresses tumorigenicity tests of animal cells for the production of biologicals. However, the tumorigenicity test described in WHO TRS 878, which involves the administration of  $10^7$  cells to ten nude mice, would not be sensitive enough to detect a trace amount of tumorigenic cellular impurities in hCTPs [2]. In addition, the *in vivo* tumorigenicity test proposed in WHO TRS 878 covers only viable animal cells used as cell substrates for manufacturing biological products but not cells used directly for therapy by transplantation into patients. Thus, to date, no suitable tumorigenicity test has been established for hCTPs.

To establish methods to detect a trace amount of tumorigenic cellular impurities in hCTPs, the usage of several new generations of highly immunodeficient animal models are proposed. Rag2- $\gamma$ C double-knockout mice [3], NOD/Shi-scid IL2R $\gamma^{\text{null}}$  (NOG) mice [4], and NOD/SCID/IL-2R $\gamma$ KO (NSG) mice [5] indicate multiple immunodeficiencies, including defects in T, B, and natural killer (NK) cells, and a reduction in the function of macrophages and dendritic cells. NOG mice exhibit extremely high engraftment rates of human HeLa S3 cells compared with T-cell-deficient nude mice and T and B-cell-deficient SCID mice [6]. NSG mice are reported to show efficient tumor formation by single human melanoma cells in combination with Matrigel, a basement membrane-like extracellular matrix extract [7]. However, for the use of these highly immunodeficient mouse strains to detect tumorigenic cellular impurities in hCTPs as a part of the quality assessment/control, the performance of the tumorigenicity tests using these strains shall be validated using well known tumor cell lines.

In the present study, we examined the tumor formation potential of HeLa cells transplanted in NOG mice with Matrigel and compared their tumorigenicity with that in nude mice. To determine the sensitivity for the detection of tumor cells contamination in non-tumorigenic human somatic cells, we mixed various dose of HeLa cells in human mesenchymal stem cells and conducted tumorigenicity tests using NOG mice and Matrigel. We also performed soft agar colony formation assay, which is commonly used to detect anchorage-independent cell growth *in vitro*, and compared tumor cell detection level by soft agar with the *in vivo* tumorigenicity test.

## 2. Materials and methods

### 2.1. Cells

Human cervical cancer HeLa cells were obtained from the Health Science Research Resources Bank (HSRRB, Osaka, Japan). The cells were maintained in Eagle's minimum essential medium (Sigma), supplemented with 10% fetal bovine serum (FBS; Sigma), 0.1 mM non-essential amino acids (Life Technologies), 50 U/ml penicillin, and 50  $\mu$ g/ml streptomycin (Life Technologies). Human mesenchymal stem cells (hMSCs) were purchased from Lonza and cultured in MSCGM™ medium (Lonza). Cells were cultured in a humidified atmosphere of 5% CO<sub>2</sub> and 95% air at 37 °C, and were passaged upon reaching 80% confluence. hMSCs were used at passage 6 and passages 6–8 for *in vivo* tumorigenicity tests and soft agar colony formation assay, respectively.

### 2.2. Preparation of cell suspensions for transplantation

Upon reaching approximately 80% confluence, cells were washed twice with phosphate buffered saline (PBS) and treated

with 0.25% trypsin-EDTA solution (Life Technologies) for detachment from culture dishes. HeLa cells and/or hMSCs were counted and prepared in 100  $\mu$ l of ice-cold HeLa cell culture medium or a 1:1 (v/v) mixture of HeLa cell culture medium and Matrigel (product #354234, BD Biosciences, San Jose, CA) for transplantation.

### 2.3. Tumorigenicity test with immunodeficient mice

Male BALB/cA nu/nu mice (nude; CLEA Japan, Inc., Tokyo) and male NOG mice maintained in the Central Institute for Experimental Animals (CIEA, Kanagawa, Japan) were used for *in vivo* tumorigenicity studies. Prepared cell suspensions were injected using 1 ml syringes with a 25 G needle (Terumo) into 8-week-old mice (n = 6 or 10). The mice were palpated weekly for 16 weeks to observe nodule formation at the injection site. Tumor size was assessed by external measurement of the length and width of the tumors in two dimensions using a caliper as soon as tumors reached measurable size. The tumor volume (TV) was calculated using the formula  $\text{volume} = 1/2 \times \text{length (mm)} \times (\text{width [mm]})^2$ . The successive engraftment was determined according to progressive nodule growth at the injection site. Mice were euthanized and necropsied when tumors reached approximately 20 mm in any dimension or when a sign of deconditioning was noted. The tumorigenicity of HeLa cells was evaluated by measuring tumor-forming capacity, which indicates the tumorigenic phenotype [8,9]. Tumor-forming capacity is defined as 50% tumor-producing dose (TPD<sub>50</sub>), which represents the threshold dose of cells forming tumors in 50% of the animals. TPD<sub>50</sub> values were calculated using the Spearman-Kärber method [10–12] at each time point. Not all animals transplanted with the highest dose formed tumors, in which case it was assumed that the tumor incidence of animals at 10 or 100 times the uppermost dose step (a dummy set of data) would have been 100% for the Spearman-Kärber method to be applicable [12].

The protocol of the present study was reviewed beforehand and approved by the Animal Ethics Committees of CIEA (Permit Number: 13041A) and the National Institute of Health Sciences (NIHS, Tokyo) (Permit Number: 359, 359-1, 359-2, 359-3). All animal experiments were performed according to the Ethical Guidelines for Animal Experimentation from the CIEA and the NIHS. All animals were sacrificed under isoflurane inhalation anaesthesia, and all efforts were made to minimize suffering.

### 2.4. Histology and immunohistochemistry

The engrafted tumors were isolated and fixed with 10% neutral buffered formalin (Wako). The paraffin-embedded sections were investigated by hematoxylin and eosin (H&E) stain and immunohistochemical studies using Bond-max stainers (Leica Biosystems). Some sections were incubated at 100 °C for 10 min in a target retrieval solution consisting of 10 mM citrate buffer (ER1; Leica Microsystems), and then placed at room temperature for 20 min. Mouse anti-human HLA class I-A, B, C monoclonal antibody (EMR8-5; Hokudo, Sapporo, Japan), and rabbit anti-vimentin monoclonal antibody (SP20; Nichirei Bioscience, Tokyo) were used as the primary antibodies. The antibodies for mouse immunoglobulin were visualized using Bond polymer refine detection kits (Leica Microsystems). Sections were counterstained with hematoxylin.

### 2.5. Soft agar colony formation assay

A soft agar colony formation assay was performed using a CytoSelect™ 96-well Cell Transformation Assay kit (CellBio labs, San Diego, CA) as previously described [13]. Prewarmed 25  $\mu$ l of 2 × DMEM/20% FBS and 25  $\mu$ l of 1.2% agar solution were mixed and



transferred onto a well of 96-well plates, and then incubated at 4 °C for 30 min to allow the bottom agar layer to solidify. HeLa cells and hMSCs were dissociated into a single cell suspension by treatment with 0.25% trypsin-EDTA solution (Life Technologies) and passed through 40  $\mu$ m nylon cell strainers (BD Falcon). Next, 25  $\mu$ l of cell suspensions containing serially diluted HeLa cells (0, 10, 20, 30, 50, and 100 cells) and hMSCs ( $1.0 \times 10^4$  cells) in DMEM/10% FBS, were mixed with 25  $\mu$ l of 2  $\times$  DMEM/20% FBS and 25  $\mu$ l of 1.2% agar. After being placed on the bottom agar layer, the top agar layers were immediately solidified at 4 °C for 10 min to avoid false-positive signals derived from sedimentation-induced contact between the cells. The plates were incubated with 100  $\mu$ l of DMEM/10% FBS per well for 10 and 20 days at 37 °C and 5% CO<sub>2</sub>. The medium was changed every 2–3 days. Colonies were lysed and quantified with CyQuant GR dye using a fluorometer equipped with a 485/520 nm filter set (Wallac 1420 ARVox multilabel counter, PerkinElmer, Boston, MA). Results were evaluated as a relative fold change of the value of negative control (hMSCs only). The lower limit of detection (LLOD) of the assay signal was calculated as the mean plus 3.3 fold the standard deviation of the measurement of the three lots of hMSCs [14].

### 3. Results

#### 3.1. The tumorigenic potential of HeLa cells in nude and NOG mice

We first tried to evaluate the tumorigenic potential of human tumorigenic cells in NOG mice in the absence or presence of Matrigel, compared with that in nude mice. Namely, we examined the tumor formation of HeLa cells transplanted into the subcutaneous spaces of mice, and tumorigenic incidence was compared between nude and NOG mice for 16 weeks (Fig. 1a–c and Table 1). The development of spontaneous tumors was not observed in non-transplant mice of either strain during the period of monitoring. Nude mice, which are traditional standards for tumorigenicity testing, showed no tumor formation when HeLa cells were transplanted at a dose of up to  $1.0 \times 10^5$  cells. On the other hand, NOG mice developed tumors with a lower cell transplantation dosage ( $1.0 \times 10^4$  cells). Transplanting HeLa cells with Matrigel considerably increased the tumor formation potential of HeLa cells in NOG mice. Notably, subcutaneous transplantation of  $1.0 \times 10^3$  HeLa cells gave rise to tumors in NOG mice when embedded with Matrigel (10/10 animals) but not without Matrigel (0/10 animals). Furthermore, 60% (6/10 animals) of NOG mice formed tumors within 16 weeks when  $1.0 \times 10^2$  HeLa cells were transplanted with Matrigel subcutaneously. Next, to compare tumor forming potential of nude mice and NOG mice more quantitatively, we calculated a 50% tumor producing dose, TPD<sub>50</sub>, of HeLa cells in NOG and nude mice. At the end of monitoring for 16 weeks, NOG mice exhibited TPD<sub>50</sub> =  $1.3 \times 10^4$  when injected with HeLa cells in the absence of

Matrigel (Table 1). As expected, tumorigenic potential of HeLa cells was enhanced 30-fold when transplanted in NOG mice compared with that in nude mice (TPD<sub>50</sub> =  $4.0 \times 10^5$  at week 16). Furthermore, tumorigenic potential of HeLa cell was enhanced 5000-fold when HeLa cells are embedded with Matrigel and transplanted in NOG mice (TPD<sub>50</sub> =  $7.9 \times 10$  at week 16) compared with that in nude mice without Matrigel. Thus, NOG mice showed superior tumor forming potential when the tumor cells are embedded with Matrigel.

Transplanted cells progressively formed a large spheroid tumor at the inoculation site without invading host subcutaneous tissue (Fig. 2d). Tumor mass increases in a dose- and time-dependent manner in both mouse strains (Fig. 2a–c). To confirm the origin of tumors engrafted in the NOG mice, embedded tissue sections were stained with anti-human HLA antibody. The immunohistochemical analysis demonstrated that the engrafted tumors originated from human cells (Fig. 2e). No histological difference was observed between tumor in nude mice and that in NOG mice (data not shown).

#### 3.2. Detection of tumors in NOG mice inoculated with HeLa cells spiked into hMSCs

Next we attempted to determine the characteristics of the test using NOG mice and Matrigel for detection of tumorigenic cellular impurities in human somatic cells. For this end, HeLa cells ( $1.0 \times 10$ ,  $1.0 \times 10^2$ ,  $1.0 \times 10^3$ , and  $1.0 \times 10^4$ ) were spiked into  $1.0 \times 10^6$  hMSCs, and then subcutaneously transplanted into NOG mice with Matrigel. Tumor formation at the transplanted site was continuously monitored for 16 weeks. Subcutaneous transplantation of hMSCs alone in NOG mice did not generate tumor in any mice during the monitoring period (Table 2). Within 16 weeks after transplantation, 50% of the NOG mice (3/6 animals) generated subcutaneous tumors derived from  $1.0 \times 10^2$  HeLa cells spiked in  $1.0 \times 10^6$  hMSCs (Fig. 3a). The TPD<sub>50</sub> of HeLa cells transplanted in NOG mice with  $1.0 \times 10^6$  hMSCs and Matrigel was  $1.0 \times 10^2$  at week 16, which was almost the same as the TPD<sub>50</sub> transplanted with HeLa cells alone (Tables 1 and 2). These results indicated that *in vivo* tumorigenicity tests using NOG mice and Matrigel are able to detect over 0.01% HeLa cell contamination in hMSCs, which is equivalent to a single tumor cell contamination in 10,000 somatic cells. To determine sensitivity of tumorigenicity tests using NOG mice, we spiked  $1.0 \times 10$  (0.0001%) and  $1.0 \times 10^2$  (0.001%) HeLa cells into hMSCs ( $1.0 \times 10^7$  cells), which was tenfold the dose used in the previous experiments, and subcutaneously transplanted them into NOG mice with Matrigel. Two and out of 6 NOG mice inoculated with  $1 \times 10^2$  HeLa cells generated subcutaneous tumors within 16 weeks when a higher dose of hMSCs was co-transplanted (Fig. 3b). It is of note that one out of 6 mice transplanted with  $1 \times 10$  HeLa cells and  $1 \times 10^7$  hMSCs also showed tumor formation. The TPD<sub>50</sub> of HeLa cells transplanted with  $1.0 \times 10^7$  hMSCs and Matrigel in NOG mice was  $1.8 \times 10^2$  at week 16 (Table 2). These results are quite




Fig. 1. Tumor incidence of HeLa cells in nude and NOG mice. The tumor formation of HeLa cells transplanted into the subcutaneous spaces of mice was examined for 16 weeks. The relationships between the dose and the tumorigenic incidence of HeLa cells in nude mice (a) and NOG without (b) or with (c) Matrigel are presented (n = 10 in each group).



**Table 1**  
Tumor-forming capacity of HeLa cells in nude and NOG mice.

Strain	Group	Tumor incidence at indicated HeLa cell dose at 16w								TPD <sub>50</sub> at week 16	Fold-change in TPD <sub>50</sub> (vs. nude mice)
		0	1 × 10	1 × 10 <sup>2</sup>	1 × 10 <sup>3</sup>	1 × 10 <sup>4</sup>	1 × 10 <sup>5</sup>	1 × 10 <sup>6</sup>	1 × 10 <sup>7</sup>		
Nude	HeLa	0/10 <sup>a</sup>	–	–	–	0/10	2/10	7/10	(10/10) <sup>b</sup>	4.0 × 10 <sup>5</sup>	1.0
NOG	HeLa	0/10	–	0/10	0/10	4/10	10/10	–	–	1.3 × 10 <sup>4</sup>	3.0 × 10
NOG	HeLa w/MG	0/10	0/10	6/10	10/10	10/10	–	–	–	7.9 × 10	5.0 × 10 <sup>3</sup>

–: Not tested.

MG: Matrigel.

<sup>a</sup> No. of mice in which tumors formed/total no. of mice inoculated.

<sup>b</sup> Since not all animals inoculated with the highest dose (10<sup>6</sup>) formed tumors, it was assumed that the tumor incidence of animals at an even higher dose step (a dummy set of data) would have been 100% for the Spearman-Kärber method to be applicable.

consistent with those without a mixture of hMSCs (Fig. 1c), demonstrating that HeLa cells can grow under subcutaneous environments of NOG mice without significant effect from co-transplanted hMSCs. Taken together, our results indicated that *in vivo* tumorigenicity tests with NOG mice in the combination with Matrigel has the ability to detect 100 HeLa cells spiked into hMSCs in almost half of mice.

Morphological observation of tumors originated from HeLa cells spiked in hMSCs and HeLa cells alone was identical (Figs. 2d and 3c). The immunohistochemical analysis of the tissue sections using anti-human HLA monoclonal antibody clearly demonstrated that the engrafted tumors originated from human cells (Fig. 3d). Vimentin, an intermediated filament protein, is known to express in the process of epithelial to mesenchymal transition and is commonly used as one of the markers of mesenchymal stem cells [15,16]. Negative staining with anti-vimentin antibody suggested that formed tumors were attributed to the exceeding growth of HeLa cells (Fig. 3e).


### 3.3. Changes of TPD<sub>50</sub> values depending on the time course

The tumor development of HeLa cells in nude and NOG mice under various conditions are shown as the transition of TPD<sub>50</sub> at

weekly intervals. Nude and NOG mice inoculated with HeLa cells without Matrigel demonstrated only a slight decrease in TPD<sub>50</sub> values from 8 weeks following injection (Fig. 4). On the other hand, TPD<sub>50</sub> values rapidly decreased until 12 weeks and then almost reached a plateau until 16 weeks when NOG mice were inoculated with cells in combination with Matrigel. These results suggest that Matrigel is able to support the growth of transplanted small number of tumor cells that cannot survive without Matrigel, and a tumor originated from small number of tumorigenic cells takes time to form visible mass.

### 3.4. Soft agar colony formation assay for detection of HeLa cell contamination

The soft agar colony formation assay is a suitable method to monitor anchorage-independent cell growth and a well-known *in vitro* assay for the detection of malignant transformed cells [17,18]. HeLa cells enclosed by soft agar showed progressive formation of colonies (Fig. 5a), whereas hMSCs did not form any colonies in a soft agar media with 1 × 10<sup>4</sup> cells/well by day 20 (Fig. 5b and c). We next spiked several concentrations of HeLa cells into 1 × 10<sup>4</sup> hMSCs to determine the minimum number of HeLa cells required for growth in a soft agar media. More than 0.2% spiked



**Fig. 2.** Characterization of subcutaneous tumors formed by transplantation with HeLa cells in nude and NOG mice. Growth curves of subcutaneous tumors formed by inoculation with various dosages of HeLa cells were presented in respective mice (a: nude; b: NOG w/o Matrigel; c: NOG w/Matrigel). The tumor volume (TV) was calculated using the formula volume = 1/2 × length (mm) × (width [mm])<sup>2</sup>. The successive engraftment was determined according to progressive nodule growth at the injection site. Mice were euthanized and necropsied when tumors reached approximately 20 mm in any dimension or when a sign of deconditioning was noted. Representative images from histology and immunohistochemistry analyses of subcutaneous tumors in NOG mice formed by transplantation with 1.0 × 10<sup>2</sup> HeLa cells suspended in Matrigel (d and e). Serial sections were stained with H&E (d) and HLA antibody (e) (magnification, 40×; scale bars, 1 mm).



**Table 2**  
Tumor-forming capacity of HeLa cells mixed in hMSCs in NOG mice.

Strain	Group	Tumor incidence at indicated HeLa cell dose at 16w					TPD <sub>50</sub> at week 16
		0	1 × 10 <sup>1</sup>	1 × 10 <sup>2</sup>	1 × 10 <sup>3</sup>	1 × 10 <sup>4</sup>	
NOG	HeLa <sup>a</sup>	–	–	–	–	6/6 <sup>b</sup>	ND
NOG	HeLa/hMSC (1 × 10 <sup>6</sup> )	0/6	0/6	3/6	6/6	6/6	1.0 × 10 <sup>2</sup>
NOG	HeLa/hMSC (1 × 10 <sup>7</sup> )	0/6	1/6	2/6	–	(6/6) <sup>c</sup>	1.8 × 10 <sup>2</sup>

–: Not tested.

ND: Not determined.

<sup>a</sup> Single dose group as a positive control.


<sup>b</sup> No. of mice in which tumors formed/total no. of mice inoculated.

<sup>c</sup> Since not all animals inoculated with the highest dose (10<sup>2</sup>) have formed tumors, it was assumed that the tumor incidence of animals at an even higher dose step (a dummy set of data) would have been 100% for the Spearman–Kärber method to be applicable.

HeLa cells gave rise to detectable colonies within 10 days (Fig. 5c). Fewer HeLa cells formed detectable colonies within 20 days (0.1%: 10 cells/well). Since the LLOD is calculated as mean + 3.3 × standard deviation (SD) [14], the LLOD of the soft agar transformation assay was 2.06 based on signals from three lots of hMSCs as a negative control (1.0 ± 0.3 [fold over the background signal]) (Fig. 5d). Referring to the LLOD, even the minimum number of HeLa cells (0.1%) gave rise to distinct detectable colonies at day 20. These results indicated that the soft agar colony formation assay was able to detect colonies generated from at least 0.1% HeLa cells spiked into hMSCs within 20 days.

#### 4. Discussion


The contamination of hCTPs with tumorigenic cells is an issue of concern for product manufacture. Although immunodeficient nude mice are commonly used to assess the tumorigenicity of cell substrates used for production of biological products, more sensitive methods are required to detect a trace amount of tumorigenic cellular impurities in hCTPs. Superior xeno-engraftment capacity of NOG mice were previously reported using HeLa S3 cells [6]. Here, in



**Fig. 4.** Comparative development of HeLa cell tumors in nude and NOG mice under various conditions. HeLa cell tumor development in nude and NOG mice under various conditions are expressed as transition of TPD<sub>50</sub> at weekly intervals. MG, Matrigel.


combination with Matrigel, we have further developed and quantitatively characterized highly sensitive *in vivo* tumorigenicity tests using NOG mice to detect trace amounts of tumorigenic cellular impurities in hCTPs. Subcutaneous transplantation into NOG mice with Matrigel allowed inoculation with 10<sup>7</sup> cells and actually achieved detection of 0.002% and 0.0001% HeLa cells spiked into hMSCs at probabilities of 50% and 17%, respectively. Moreover, the TPD<sub>50</sub> of our methods was 5000-fold higher than that of tumorigenicity tests using traditional nude mice at 16 weeks following injection. We also showed that soft agar colony formation assay could detect at least 0.1% HeLa cells spiked into hMSCs within 3 weeks as a representative *in vitro* tumorigenicity tests.

WHO TRS 878 recommends T-cell deficient nude mice for tumorigenicity tests. However, tumorigenicity tests using nude mice are not sensitive enough for detecting trace amounts of



**Fig. 3.** Detection of tumors in NOG mice transplanted with HeLa cells spiked into hMSCs. The cohorts inoculated HeLa cells spiked in 10<sup>6</sup> and 10<sup>7</sup> hMSCs cells were observed for 16 weeks, respectively. The relationships between the cell dose and the tumorigenic incidence of HeLa spiked in 1.0 × 10<sup>6</sup> (a) and 1.0 × 10<sup>7</sup> (b) hMSCs cells in NOG mice are presented (n = 6 in each group). Representative images from histology and immunohistochemistry analyses of subcutaneous tumors in NOG mice formed by transplantation with 1.0 × 10<sup>4</sup> HeLa cells mixed in 1.0 × 10<sup>6</sup> hMSCs suspended in Matrigel (c, d, and e). Serial sections were stained with H&E (c), HLA antibody (d), and Vimentin antibody (e) (magnification, 100×; scale bars, 500 μm).





**Fig. 5.** Soft agar colony formation assay of HeLa cells. HeLa cells enclosed in soft agar showed progressive formation of colonies (a), whereas hMSCs did not form any colonies in a soft agar media with  $1.0 \times 10^4$  cells/well by day 20 (b). Arrows indicate the colonies of HeLa cells (magnification,  $100\times$ ; scale bars,  $250 \mu\text{m}$ ). HeLa cells (0%, 0 cells; 0.1%, 10 cells; 0.2%, 20 cells; 0.3%, 30 cells; 0.5%, 50 cells; 1%, 100 cells; 3%, 300 cells; 10%, 1000 cells) were spiked into  $1.0 \times 10^4$  hMSCs and grown in soft agar for 10 and 20 days (c). HeLa cells spiked into hMSCs and three lots of hMSCs were grown in soft agar for 20 days (d). The lower limit of detection (LLOD) was calculated as the mean plus 3.3 fold the standard deviation of the measurement of the three lots of hMSCs. Quantification of the results is described in (d). Cell growth was quantified using a CytoSelect™ kit. Results were expressed as a relative fold change of the value of negative control (hMSC lot A). Error bars represent the standard deviation of the measurements ( $n = 3$ ).

tumorigenic cells. In fact, the TPD<sub>50</sub> was previously reported to be  $6.3 \times 10^4$  and  $3.2 \times 10^6$  of human tumorigenic HeLa cells and HEK293 cells, respectively [19]. In the present study, tumorigenicity tests using nude mice transplanted subcutaneously with HeLa cells indicated TPD<sub>50</sub> =  $4.0 \times 10^5$  (Table 1). Our method using NOG mice and Matrigel tremendously improved the TPD<sub>50</sub>, and its value was  $7.9 \times 10$  when transplanted with HeLa cells (Table 1). In addition to nude mice, NOD/SCID mice are frequently used for tumor biology and xeno-graft research. To establish the NOD/SCID mouse strain, SCID mutation impairing T and B cell lymphocyte development was transferred onto a non-obese diabetic background deficient in NK cell function [20,21]. NOD/SCID mice are known to demonstrate a high incidence of thymic lymphomas with age [22,23]. The NOG mice used in this study were generated by mating C57BL/6J- $\gamma\text{C}^{\text{null}}$  and NOD/Shi-scid mice [4]. The IL2 receptor common  $\gamma$ -chain is indispensable for IL2, IL4, IL7, IL9, IL15, and IL21 high affinity binding and signaling, and is also thought to play a key role in mediating susceptibility to thymic lymphomas in mice [5]. NOG mice never show the high incidence of thymic lymphomas characterized in NOD/SCID mice [24], which was consistent with our results. The incidence of thymic lymphomas often shortens the lifespans of mice and would lead to confusing tumorigenicity test results. Tumorigenicity tests using NOG mice are also able to resolve the issues arising from the pathological properties of NOD/SCID mice.

Matrigel is a tissue basement membrane matrix rich in extracellular matrix (ECM) proteins that was originally isolated from the mouse tumor the murine Engelbreth-Holm-Swarm sarcoma [25]. Matrigel is known to facilitate human tumor xenograft growth in rodents [26], which was confirmed in the present study using HeLa cells and NOG mice, presumably by providing the extracellular environment for tumor growth. However, Matrigel is derived from

mouse cells, not of human origin. Since the human tissue-mimetic microenvironment is preferable for the estimation of tumorigenicity of hCTPs in clinical settings, development of a new human-derived ECM proteins as an alternative to Matrigel may be necessary for more precise estimation of the tumorigenic properties of hCTPs inoculated into human tissues.

Soft agar colony formation assay is an anchorage-independent growth assay in soft agar, which is considered the most stringent *in vitro* assay to detect transformed cells. In this study, the soft agar colony formation assay was able to detect colonies generated from at least 0.1% HeLa cells spiked into hMSCs within 20 days (Fig. 5c). Based on a standard curve by plotting the assay signals, the LLOD, which was calculated as 2.06 (Fig. 5d), corresponded to approximately 0.02% HeLa cell contamination. This method is easy, inexpensive, and time-saving, but its sensitivity to detect transformed cells is lower compared with *in vivo* tumorigenicity tests using NOG mice and Matrigel (Fig. 3a–b and Table 2). Understanding the abilities and limitations of individual tumorigenicity tests, we need to select appropriate tests to evaluate hCTPs.

Products derived from somatic cells, e.g. hMSCs, are extensively developed in industry all over the world. To our knowledge, human adult somatic cells have not yet been reported to form tumor after clinical application until now. Although at least four research papers have previously reported the *in vitro* spontaneous transformation of hMSCs [27–30], two of them were retracted later because their observations turned out to have come from cross-contamination with tumorigenic cells [31,32]. In the other two of the four papers, the immortal growth was easily detected *in vitro* [29,30], indicating that the process control to avoid cross-contamination and the monitoring of cell growth at/after the limit of *in vitro* cell age used for production would be more critical for the quality of products derived from human somatic cells, rather



than the detection of malignant transformation during cell processing.

HeLa cells, the oldest immortal and tumorigenic human cell line in the history of the world, are well-characterized, currently available almost anywhere in the world, and extensively used for a wide variety of biomedical research. There have been many reports of HeLa cell cross-contamination in mammalian cell lines, and the use of HeLa-contaminated cell lines has been a big problem over several decades [33,34]. Therefore, we employed HeLa cells as a model of tumorigenic cellular impurities in the present study.

Alternatively, we also expect the application of our method for detecting the tumorigenic contamination of products derived from human pluripotent stem cells (hPSCs) as well as human somatic cells. It is actually being attempted for hPSCs such as embryonic stem cells to differentiate into hMSCs and they are expected to be used as or for hCTPs [35–37]. Although a lot of allogenic applications of primary hMSCs are currently being developed, hMSCs derived from clonal hPSCs are presumed to have an advantage of quality control in respect to robust manufacturing and restricted virus infection. However, since undifferentiated hPSCs are tumorigenic, the contamination of the final products with residual PSCs is one of the biggest concerns [2]. Recently, we showed that the NOG mouse was the most sensitive animal in terms of tumor formation from human induced pluripotent stem cells (hiPSCs) among several immunosuppressed animals, with the TPD<sub>50</sub> value in between 10<sup>2</sup> and 10<sup>3</sup>, when injected subcutaneously with Matrigel [38]. In the same paper, we also showed that, when hiPSCs were co-administered with Matrigel and retinal pigment epithelial cells derived from hiPSCs, the TPD<sub>50</sub> value was increased to approximately 10<sup>3</sup> to 10<sup>4</sup>, presumably attributable to paracrine action of pigment epithelium-derived factor with a pro-apoptotic effect on hiPSCs [38]. These results, combined with those in the present study, suggest that the *in vivo* tumorigenicity test using NOG mice is commonly applicable to the detection of tumorigenic or pluripotent cellular impurities in a variety of hCTPs.

To our knowledge, the *in vivo* tumorigenicity test using NOG mice in the present study is one of the most sensitive methods to detect a trace amount of tumorigenic cells in normal cells. However, hCTPs may contain quite a large number of cells in clinical setting. In some cases of cellular therapy, one hundred million or more cells are necessary [39]. For example, 1 × 10<sup>8</sup> or more cells are required for the treatment of liver disease [40]. For one patient with heart failure, preferably more than one billion cardiomyocytes need to be transplanted [41]. The sensitivity of the assay methods in the present study would be insufficient to evaluate tumorigenicity of hCTPs like above. The problem is that no method is currently available to detect one or a few tumorigenic cells in more than 10<sup>7</sup> normal cells. Further studies are necessary to develop more sensitive tests for hCTPs. Improvements of the tests (e.g. development of new animal models or matrix better than Matrigel), *in vivo*/*in vitro* tumorigenicity tests for cells cultured beyond the limit of *in vitro* cell age used for production, or combinations of the tests (e.g. *in vivo* test for cell colonies in soft agar) may be options.

Another problem is that scientific interpretations of the results from *in vivo* tumorigenicity tests have not been established, because the tests have not been well-characterized from a viewpoint of the evaluation of hCTPs. In the present study, we quantitatively characterized the *in vivo* tumorigenicity test, and determined its ability of detection of a trace amount of tumorigenic cells. According to the results in Table 2, the *in vivo* tumorigenicity test using NOG mice and Matrigel detects as low as 0.0001% cellular impurities at a probability of 17%, in case that the tumorigenicity of the impurities is comparable to that of HeLa cells in hMSCs. Conversely, the false negative rate (x) of an NOG mouse inoculated with the hCTP containing the 0.0001% cellular impurities is

(100–17=) 83%. Thus, the false negative rate (y) of n mice can be expressed as follows:

$$y = x^n$$

Hence, we obtain:

$$n = \log y / \log x$$

For example, when permitting 1% false negative rate in the whole test, 25 (=log(0.01)/log(0.83)) mice are necessary to prove the absence of the 0.0001% cellular impurities. In other words, if 25 or more mice are used for a tumorigenicity test, and if no tumor formation is observed in all the mice, the test result indicates, at a false negative rate of 1%, that the hCTPs is not contaminated with 0.0001% or more HeLa-like tumorigenic cells.

This well-characterized test can be applicable at least to quality assessment/control of hCTPs. Namely, although “Negative in the NOG mouse test” may not directly guarantee the “safety” of the final product, the negative result can be one of critical “quality” attributes to demonstrate the absence a certain number of tumorigenic cells. To date, no international/domestic regulatory authority has issued guidelines for the tumorigenicity tests of hCTPs. Further studies are necessary to establish and share principles, paradigms, and standardized methods for measurements and interpretations of tumorigenicity of hCTPs, which will greatly contribute to the development of safe hCTPs of high quality.

## 5. Conclusions

In this study, we have demonstrated that NOG mice in combination with Matrigel demonstrated superior efficiency in engraftment of HeLa cells, compared with nude mice that are recommended in WHO guideline. They also showed an ability to detect as little as 100 HeLa cells present in hMSCs in almost half of mice. These results suggest that the *in vivo* tumorigenicity test using NOG mice with Matrigel is a highly sensitive and quantitative method to detect a trace amount of tumorigenic cellular impurities in human somatic cells, which can be useful in quality assessment of hCTPs.

## Acknowledgments

This work was supported by a Strategic Fund for the Promotion of Science and Technology from the Japan Science and Technology Agency (AIRO-KAISHO Project), and Research Grants from the Japanese Ministry of Health, Labour and Welfare (H23-SAISEI-IPPAN-005, H24-IYAKU-SHITEI-027, H25-JITSUYOKA(SAISEI)-IPPAN-008, and Marketing Authorization Facilitation Program for Innovative Therapeutic Products).

## Conflict of Interest

All authors declare no conflict of interest.

## References

- [1] World Health Organization. Requirements for the use of animal cells as *in vitro* substrates for the production of biologicals. WHO technical report series. 1998, No 878 Annex 1.
- [2] Kuroda T, Yasuda S, Sato Y. Tumorigenicity studies for human pluripotent stem cell-derived products. *Biological Pharm Bull* 2013;36(2):189–92.
- [3] Goldman JP, Blundell MP, Lopes L, Kinnon C, Di Santo JP, Thrasher AJ. Enhanced human cell engraftment in mice deficient in RAG2 and the common cytokine receptor gamma chain. *Br J Haematol* 1998;103(2):335–42.
- [4] Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K, et al. NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. *Blood* 2002;100(9):3175–82.



- [5] Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, Chaleff S, et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. *J Immunol* 2005;174(10):6477–89.
- [6] Machida K, Suemizu H, Kawai K, Ishikawa T, Sawada R, Ohnishi Y, et al. Higher susceptibility of NOG mice to xenotransplanted tumors. *J Toxicol Sci* 2009;34(1):123–7.
- [7] Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. *Nature* 2008;456(7222):593–8.
- [8] Lewis Jr AM, Alling DW, Banks SM, Soddu S, Cook JL. Evaluating virus-transformed cell tumorigenicity. *J virological Methods* 1999;79(1):41–50.
- [9] Omeir RL, Teferedegne B, Foseh GS, Beren JJ, Snoy PJ, Brinster LR, et al. Heterogeneity of the tumorigenic phenotype expressed by Madin-Darby canine kidney cells. *Comp Med* 2011;61(3):243–50.
- [10] U.S. Food and Drug Administration. Proposed use of a 50% limit of detection value in defining uncertainty limits in the validation of presence-absence microbial detection methods. 2006. Final Report and Executive Summaries from the AOAC International Presidential Task Force on Best Practices in Microbiological Methodology Appendix K.
- [11] Hamilton MA, Russo RC, Thurston RV. Trimmed Spearman-Kärber method for estimating Median Lethal concentrations in toxicity bioassays. *Environ Sci Tech* 1977;11(7):714–9.
- [12] Lorenz RG, Bogel K. Methods of calculation. In: Kaplan MM, Koprowski H, editors. *Laboratory techniques in rabies*. 3rd ed. 1973. p. 321–35.
- [13] Kuroda T, Yasuda S, Kusakawa S, Hirata N, Kanda Y, Suzuki K, et al. Highly sensitive in vitro methods for detection of residual undifferentiated cells in retinal pigment epithelial cells derived from human iPSCs. *PLoS one* 2012;7(5):e37342.
- [14] Miller JN, Miller JC. *Statistics and Chemometrics for Analytical Chemistry*. 5th ed. 2005. Published by Pearson Education Canada.
- [15] Kato N, Shimmura S, Kawakita T, Miyashita H, Ogawa Y, Yoshida S, et al. Beta-catenin activation and epithelial-mesenchymal transition in the pathogenesis of pterygium. *Invest Ophthalmol Vis Sci* 2007;48(4):1511–7.
- [16] Kokkinos MI, Wafai R, Wong MK, Newgreen DF, Thompson EW, Waltham M. Vimentin and epithelial-mesenchymal transition in human breast cancer-observations in vitro and in vivo. *Cells Tissues Organs* 2007;185(1–3):191–203.
- [17] Cifone MA, Fidler IJ. Correlation of patterns of anchorage-independent growth with in vivo behavior of cells from a murine fibrosarcoma. *Proc Natl Acad Sci U. S. A.* 1980;77(2):1039–43.
- [18] Boyd DD, Levine AE, Brattain DE, McKnight MK, Brattain MG. Comparison of growth requirements of two human intratumoral colon carcinoma cell lines in monolayer and soft agarose. *Cancer Res* 1988;48(9):2469–74.
- [19] Lewis AM. *Regulatory Implications of Neoplastic cell substrate tumorigenicity*. 2005. [http://www.fda.gov/ohrms/dockets/ac/05/slides/5-4188s1\\_2.ppt](http://www.fda.gov/ohrms/dockets/ac/05/slides/5-4188s1_2.ppt) [Last accessed 3.12.2014].
- [20] Koyanagi Y, Tanaka Y, Tanaka R, Misawa N, Kawano Y, Tanaka T, et al. High levels of viremia in hu-PBL-NOD-scid mice with HIV-1 infection. *Leukemia* 1997;11(Suppl 3):109–12.
- [21] Shultz LD, Schweitzer PA, Christianson SW, Gott B, Schweitzer IB, Tennent B, et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. *J Immunol* 1995;154(1):180–91.
- [22] Prochazka M, Gaskins HR, Shultz LD, Leiter EH. The nonobese diabetic scid mouse: model for spontaneous thymomagenesis associated with immunodeficiency. *Proc Natl Acad Sci U. S. A.* 1992;89(8):3290–4.
- [23] Christianson SW, Greiner DL, Hesselton RA, Leif JH, Wagar EJ, Schweitzer IB, et al. Enhanced human CD4+ T cell engraftment in beta2-microglobulin-deficient NOD-scid mice. *J Immunol* 1997;158(8):3578–86.
- [24] Kato C, Fujii E, Chen YJ, Endaya BB, Matsubara K, Suzuki M, et al. Spontaneous thymic lymphomas in the non-obese diabetic/Shi-scid, IL-2R gamma (null) mouse. *Lab Anim* 2009;43(4):402–4.
- [25] Kleinman HK, McGarvey ML, Hassell JR, Star VL, Cannon FB, Laurie GW, et al. Basement membrane complexes with biological activity. *Biochemistry* 1986;25(2):312–8.
- [26] Fridman R, Giaccone G, Kanemoto T, Martin GR, Gazdar AF, Mulshine JL. Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines. *Proc Natl Acad Sci U. S. A.* 1990;87(17):6698–702.
- [27] Rosland GV, Svendsen A, Torsvik A, Sobala E, McCormack E, Immervoll H, et al. Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. *Cancer Res* 2009;69(13):5331–9.
- [28] Rubio D, García-Castro J, Martín MC, de la Fuente R, Cigudosa JC, Lloyd AC, et al. Spontaneous human adult stem cell transformation. *Cancer Res* 2005;65(8):3035–9.
- [29] Tang DQ, Wang Q, Burkhardt BR, Litherland SA, Atkinson MA, Yang LJ. In vitro generation of functional insulin-producing cells from human bone marrow-derived stem cells, but long-term culture running risk of malignant transformation. *Am J Stem Cells* 2012;1(2):114–27.
- [30] Wang Y, Huso DL, Harrington J, Kellner J, Jeong DK, Turney J, et al. Outgrowth of a transformed cell population derived from normal human BM mesenchymal stem cell culture. *Cytherapy* 2005;7(6):509–19.
- [31] García S, Bernad A, Martín MC, Cigudosa JC, García-Castro J, de la Fuente R. Pitfalls in spontaneous in vitro transformation of human mesenchymal stem cells. *Exp Cell Res* 2010;316(9):1648–50.
- [32] Torsvik A, Rosland GV, Svendsen A, Molven A, Immervoll H, McCormack E, et al. Spontaneous malignant transformation of human mesenchymal stem cells reflects cross-contamination: putting the research field on track – letter. *Cancer Res* 2010;70(15):6393–6.
- [33] Chatterjee R. Cell biology. When 60 lines don't add up. *Science* 2007;315(5814):929.
- [34] Buehring GC, Eby EA, Eby MJ. Cell line cross-contamination: how aware are mammalian cell culturists of the problem and how to monitor it? *Vitro Cell Dev Biol Animal* 2004;40(7):211–5.
- [35] Jung Y, Bauer G, Nolte JA. Concise review: Induced pluripotent stem cell-derived mesenchymal stem cells: progress toward safe clinical products. *Stem Cells* 2012;30(1):42–7.
- [36] Chen YS, Pelekanos RA, Ellis RL, Horne R, Wolvetang EJ, Fisk NM. Small molecule mesengenic induction of human induced pluripotent stem cells to generate mesenchymal stem/stromal cells. *Stem cells Transl Med* 2012;1(2):83–95.
- [37] Kimbrel EA, Kouris NA, Yavarian GJ, Chu J, Qin Y, Chan A, et al. Mesenchymal stem cell population derived from human pluripotent stem cells displays potent immunomodulatory and therapeutic properties. *Stem Cells Dev* 2014;23(14):1611–24.
- [38] Kanemura H, Go MJ, Nishishita N, Sakai N, Kamao H, Sato Y, et al. Pigment epithelium-derived factor secreted from retinal pigment epithelium facilitates apoptotic cell death of iPSC. *Sci Reports* 2013;3:2334.
- [39] Hayashi E, Hosoda T. Therapeutic application of cardiac stem cells and other cell types. *BioMed Res Int* 2013;2013:736815.
- [40] Ohashi K, Park F, Kay MA. Hepatocyte transplantation: clinical and experimental application. *J Mol Med* 2001;79(11):617–30.
- [41] Chong JJ, Yang X, Don CW, Minami E, Liu YW, Weyers JJ, et al. Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. *Nature* 2014;510(7504):273–7.





# A Novel *In Vitro* Method for Detecting Undifferentiated Human Pluripotent Stem Cells as Impurities in Cell Therapy Products Using a Highly Efficient Culture System

Keiko Tano<sup>1,2</sup>, Satoshi Yasuda<sup>2</sup>, Takuya Kuroda<sup>2</sup>, Hirohisa Saito<sup>3</sup>, Akihiro Umezawa<sup>1</sup>, Yoji Sato<sup>2,4,5,6\*</sup>

**1** Department of Reproductive Biology, National Research Institute for Child Health and Development, Tokyo, Japan, **2** Division of Cellular & Gene Therapy Products, National Institute of Health Sciences, Tokyo, Japan, **3** National Research Institute for Child Health and Development, Tokyo, Japan, **4** Department of Quality Assurance Science for Pharmaceuticals, Graduate School of Pharmaceutical Sciences, Nagoya City University, Aichi, Japan, **5** Department of Cellular & Gene Therapy Products, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan, **6** Department of Translational Pharmaceutical Sciences, Graduated School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan

## Abstract

Innovative applications of cell therapy products (CTPs) derived from human pluripotent stem cells (hPSCs) in regenerative medicine are currently being developed. The presence of residual undifferentiated hPSCs in CTPs is a quality concern associated with tumorigenicity. However, no simple *in vitro* method for direct detection of undifferentiated hPSCs that contaminate CTPs has been developed. Here, we show a novel approach for direct and sensitive detection of a trace amount of undifferentiated human induced pluripotent stem cells (hiPSCs) using a highly efficient amplification method in combination with laminin-521 and Essential 8 medium. Essential 8 medium better facilitated the growth of hiPSCs dissociated into single cells on laminin-521 than in mTeSR1 medium. hiPSCs cultured on laminin-521 in Essential 8 medium were maintained in an undifferentiated state and they maintained the ability to differentiate into various cell types. Essential 8 medium allowed robust hiPSC proliferation plated on laminin-521 at low cell density, whereas mTeSR1 did not enhance the cell growth. The highly efficient culture system using laminin-521 and Essential 8 medium detected hiPSCs spiked into primary human mesenchymal stem cells (hMSCs) or human neurons at the ratio of 0.001%–0.01% as formed colonies. Moreover, this assay method was demonstrated to detect residual undifferentiated hiPSCs in cell preparations during the process of hMSC differentiation from hiPSCs. These results indicate that our highly efficient amplification system using a combination of laminin-521 and Essential 8 medium is able to detect a trace amount of undifferentiated hPSCs contained as impurities in CTPs and would contribute to quality assessment of hPSC-derived CTPs during the manufacturing process.

**Citation:** Tano K, Yasuda S, Kuroda T, Saito H, Umezawa A, et al. (2014) A Novel *In Vitro* Method for Detecting Undifferentiated Human Pluripotent Stem Cells as Impurities in Cell Therapy Products Using a Highly Efficient Culture System. PLoS ONE 9(10): e110496. doi:10.1371/journal.pone.0110496

**Editor:** Graca Almeida-Porada, Wake Forest Institute for Regenerative Medicine, United States of America

**Received:** March 28, 2014; **Accepted:** September 16, 2014; **Published:** October 27, 2014

**Copyright:** © 2014 Tano et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability:** The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper and its Supporting Information files.

**Funding:** This work was supported by Research Grants from the Japanese Ministry of Health, Labour and Welfare (H23-SAISEI-IPPAN-004, H23-SAISEI-IPPAN-005, H24-IYAKU-SHITEI-027, H25-JITSUYOKA(SAISEI)-IPPAN-008, and Marketing Authorization Facilitation Program for Innovative Therapeutic Products), <http://www.mhlw.go.jp/english/policy/other/research-projects/index.html>. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** The authors have declared that no competing interests exist.

\* Email: [yoji@nihs.go.jp](mailto:yoji@nihs.go.jp)

## Introduction

Cell therapy products (CTPs) are expected to offer promising treatments for serious and life-threatening diseases for which no adequate therapy is currently available. An increasing number of CTPs derived from human pluripotent stem cells (hPSCs), i.e. induced pluripotent stem cells (hiPSCs) and embryonic stem cells (hESC), are being developed for regenerative medicine/cell therapy because of their infinite self-renewal capacity and their ability to differentiate into various types of cells. Quality assessment of CTPs is critical to ensure their safety and efficacy for clinical application [1]. CTPs derived from hPSCs possibly include the cells of interest and also other cells such as undifferentiated cells, precursor cells and other differentiated cells. The presence of residual undifferentiated cells in CTPs derived from hPSCs is one of the most serious concerns for tumorigenicity

because the undifferentiated hPSCs have a capacity to form teratoma in animals [1–4]. Hentze et al. previously reported that hundreds of undifferentiated hESCs were enough to produce a teratoma in immunodeficient SCID mice [5]. We cannot exclude the possibility that a trace amount of residual undifferentiated hPSCs in CTPs cause ectopic tissue formation, tumor development and/or malignant transformation after transplantation. Therefore, establishment of a detection method for residual undifferentiated cells is necessary for the safety and quality assessment of CTPs derived from hPSCs.

An *in vivo* teratoma formation assay is the only method to directly assess tumorigenicity of undifferentiated cells, but this assay is costly and time-consuming [2,3]. Several *in vitro* methods, such as flow cytometry and quantitative real-time PCR (qRT-PCR) analysis, can also detect residual undifferentiated hPSCs in CTPs [2,3]. Our previous report has shown that flow cytometry